Clinical Research Papers:
Clinical outcome of intensity modulated radiotherapy for carcinoma showing thymus-like differentiation
Metrics: PDF 1125 views | HTML 1662 views | ?
Fangfang Kong1,2, Hongmei Ying1,2, Ruiping Zhai1,2, Chengrun Du1,2, Shuang Huang1,2,3, Junjun Zhou1,2, Xiayun He1,2, Chaosu Hu1,2, Zhuoying Wang2,4, Tuanqi Sun2,4 and Qinghai Ji2,4
1 Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R. China
2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China
3 Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, P. R. China
4 Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Shanghai, P.R. China
Hongmei Ying, email:
Keywords: intensity-modulated radiotherapy; IMRT; radiotherapy; carcinoma showing thymus-like differentiation; CASTLE
Received: March 15, 2016 Accepted: September 02, 2016 Published: September 08, 2016
Purpose: To evaluate the efficacy and toxicity of adjuvant intensity-modulated radiotherapy (IMRT) after surgery for carcinoma showing thymus-like differentiation (CASTLE).
Methods: Between September 2008 and June 2015, 14 CASTLE patients were retrospectively enrolled. The clinical features, treatment procedure and clinical outcomes were reviewed. All patients received postoperative IMRT. The radiation doses ranged from 56Gy/28 fractions to 66Gy/33 fractions. Treatment-related toxicities were graded by National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0.
Results:After a median follow-up period of 42 months, only one patient suffered local recurrence and distant metastasis. The most frequently seen acute toxicities were mucositis and dermatitis (grade 1-2). No grade 3-4 toxicities were observed.
Conclusions: Although based upon a small series of consecutively treated patients, our study showed that adjuvant IMRT provides satisfactory local-regional control for CASTLE, with acceptable toxicities. Further studies are still warranted to clarify our findings.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.